

ABSTRACT OF THE DISCLOSURE

Methods of preventing neural tissue damage caused by ADP-ribosylation of eucaryotic elongation factor-2 (EF-2) are disclosed. These methods are especially useful in the treatment of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and other cognitive disorders of mammals. Also described are methods to screen for drugs that would be useful for treating such diseases.